These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24107524)

  • 41. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD.
    Schachter EN
    Drugs Today (Barc); 2013 Jul; 49(7):437-46. PubMed ID: 23914352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
    Dhungana S; Criner GJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
    Malerba M; Radaeli A; Santini G; Morjaria J; Mores N; Mondino C; Macis G; Montuschi P
    Expert Opin Drug Discov; 2018 Jun; 13(6):563-577. PubMed ID: 29616842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.
    Pulido-Rios MT; McNamara A; Obedencio GP; Ji Y; Jaw-Tsai S; Martin WJ; Hegde SS
    J Pharmacol Exp Ther; 2013 Aug; 346(2):241-50. PubMed ID: 23685545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.
    Chiu MH; Al-Majed NS; Stubbins R; Pollmann D; Sandhu RK
    BMC Res Notes; 2016 Jun; 9():310. PubMed ID: 27301406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability.
    Doty A; Schroeder J; Vang K; Sommerville M; Taylor M; Flynn B; Lechuga-Ballesteros D; Mack P
    AAPS PharmSciTech; 2018 Feb; 19(2):837-844. PubMed ID: 29019170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ▼Umeclidinium: another LAMA for COPD.
    Drug Ther Bull; 2015 Jul; 53(7):81-4. PubMed ID: 26159701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacology, toxicology and clinical safety of glycopyrrolate.
    Chabicovsky M; Winkler S; Soeberdt M; Kilic A; Masur C; Abels C
    Toxicol Appl Pharmacol; 2019 May; 370():154-169. PubMed ID: 30905688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
    Prescrire Int; 2014 Dec; 23(155):288. PubMed ID: 25629143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aclidium bromide (Tudorza Pressair) for COPD.
    Med Lett Drugs Ther; 2012 Dec; 54(1405):99-100. PubMed ID: 23223246
    [No Abstract]   [Full Text] [Related]  

  • 51. Glycopyrronium for inhalation. COPD: another antimuscarinic with cardiac adverse effects that require monitoring.
    Prescrire Int; 2014 Feb; 23(146):36-9. PubMed ID: 24669382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glycopyrrolate/formoterol (Bevespi Aerosphere) for COPD.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):130-132. PubMed ID: 27701364
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
    Rodrigo GJ; Plaza V
    Chest; 2014 Aug; 146(2):309-317. PubMed ID: 24556877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD.
    Wan Z; Laine DI; Yan H; Zhu C; Widdowson KL; Buckley PT; Burman M; Foley JJ; Sarau HM; Schmidt DB; Webb EF; Belmonte KE; Palovich M
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4560-2. PubMed ID: 19616944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of tiotropium on COPD exacerbations: A systematic review.
    Halpin DM; Vogelmeier C; Pieper MP; Metzdorf N; Richard F; Anzueto A
    Respir Med; 2016 May; 114():1-8. PubMed ID: 27109805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler.
    Self TH; Ellingson S
    Am J Med; 2017 Nov; 130(11):1251-1254. PubMed ID: 28757318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD.
    Mete A; Bowers K; Bull RJ; Coope H; Donald DK; Escott KJ; Ford R; Grime K; Mather A; Ray NC; Russell V
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6248-53. PubMed ID: 24144851
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
    Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
    Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.